Amixicile, a novel inhibitor of pyruvate:Ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4103-4111

  Warren, Cirle A ^a,b   Van Opstal, Edward ^a   Ballard, T Eric ^b,c   Kennedy, Andrew ^b   Wang, Xia ^a   Riggins, Mary ^a   Olekhnovich, Igor ^a   Warthan, Michelle ^a   Kolling, Glynis L ^a   Guerrant, Richard L ^a,b   Macdonald, Timothy L ^b   Hoffman, Paul S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIXICILE; ANTIBIOTIC AGENT; CLINDAMYCIN; COLISTIN; FIDAXOMICIN; GENTAMICIN; METRONIDAZOLE; NITAZOXANIDE; PROPYLAMINE; PYRUVATE SYNTHASE; UNCLASSIFIED DRUG; VANCOMYCIN; VPC 161183; VPC 161195; VPC 161219; VPC 161282; VPC 162096; VPC 162125; VPC 162134; VPC 16A1011; VPC 16B1094; VPC 16B2031;

ANAEROBIC BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; CAMPYLOBACTER JEJUNI; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE FLORA; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENCE RISK; STRUCTURE ACTIVITY RELATION; SURVIVAL; SURVIVAL RATE; WEIGHT GAIN; WEIGHT REDUCTION;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; BENZAMIDES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MICE; MICROBIAL SENSITIVITY TESTS; PYRUVATE SYNTHASE; THIAZOLES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84864383200     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00360-12     Document Type: Article

References (42)

1. Ballard TE, et al. 2010. Biological activity of modified and exchanged 2-amino-5-nitrothiazole amide analogues of nitazoxanide. Biorg. Med. Chem. Lett. 20:3537-3539.
2. Ballard TE, et al. 2011. Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity. Chem. Med. Chem. 6:362-377.
3. Carroll KC, Bartlett JG. 2011. Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu. Rev. Microbiol. 65:501-521.
4. Chabrière E, Volbeda A, Fontecilla-Camps JC, Roth M, Charon MH. 1999. Combination of methods used in the structure solution of pyruvate: ferredoxin oxidoreductase from two crystal forms. Acta Crystallogr. D Biol. Crystallogr. 55:1546 -1554.
5. Chen X, et al. 2008. A mouse model of Clostridium difficile-associated disease. Gastroenterology 135:1984 -1992.
6. Clinical and Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2009. M100-S19. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Cocanour CS. 2011. Best strategies in recurrent or persistent Clostridium difficile infection. Surg. Infect. 12:235-239.
9. Debache K, et al. 2011. Experimental treatment of Neospora caninum-infected mice with the arylimidamide DB750 and the thiazolide nitazoxanide. Exp. Parasitol. 129:95-100.
10. de Carvalho LP, Lin G, Jiang X, Nathan CC. 2009. Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. J. Med. Chem. 52:5789-5792.
11. Dubreuil L, Houcke X, Mouton Y, Rossignol JF. 1996. In vitro evaluation of the activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 40:2266-2270. (Pubitemid 26328028)
12. Gerding DN. 2012. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov. Med. 13:75-83.
13. Goldstein EJC, et al. 2011. Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of Clostridium difficile infection. Antimicrob. Agents Chemother. 55:5194-5199.
14. Finegold SM, Molitoris D, Väisänen ML. 2009. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob. Agents Chemother. 53:281-286.
15. Hemphill A, Mueller J, Esposito M. 2006. Nitazoxanide, a broadspectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin. Pharmacother. 7:953-964.
16. Hoffman PS, et al. 2007. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori and selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob. Agents Chemother. 51:868-876. (Pubitemid 46355269)
17. Horner DS, Hirt RP, Embley TM. 1999. A single eubacterial origin of eukaryotic pyruvate:ferredoxin oxidoreductase genes: implications for the evolution of anaerobic eukaryotes. Mol. Biol. Evol. 16:1280-1291. (Pubitemid 29409872)
18. Kelly CP, Pothoulakis C, LaMont JT. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262. (Pubitemid 24034138)
19. Korba BE, et al. 2008. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 77:56-63.
20. Louie TJ, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
21. Mahony DE, et al. 1999. Antimicrobial activity of synthetic bismuth compounds against Clostridium difficile. Antimicrob. Agents Chemother. 43:582-588. (Pubitemid 29109522)
22. McVay CS, Rolfe RD. 2000. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44:2254-2258. (Pubitemid 30650864)
23. Mullane KM, Gorbach S. 2011. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev. Anti Infect. Ther. 9:767-777.
24. Mullane KM, et al. 2011. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis. 53:440-447.
25. Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. 2009. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin. Infect. Dis. 48:e41-e46.
26. Pankuch GA, Appelbaum PC. 2006. Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrob. Agents Chemother. 50:1112-1117. (Pubitemid 43327824)
27. Pawlowski SW, et al. 2010. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J. Infect. Dis. 202:1708-1712.
28. Redelings MD, Sorvillo F, Mascola L. 2007. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 13:1417-1419. (Pubitemid 47510317)
29. Ricciardi R, Rotherberger DA, Madoff RD, Baxter NN. 2007. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch. Surg. 142:624-631. (Pubitemid 47080440)
30. Shamir ER, et al. 2010. Nitazoxanide inhibits biofilm production and hemagglutination by enteroaggregative Escherichia coli strains by blocking assembly of AafA fimbriae. Antimicrob. Agents Chemother. 54:1526-1533.
31. Sisson G, et al. 2002. Enzymes associated with the reductive activation and action of nitazoxanide, nitrofurans and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 46:2116-2123. (Pubitemid 34665905)
32. Stiefel U, Pultz JJ, Helfand MS, Donskey CJ. 2004. Increased susceptibility to vancomycin-resistant enterococcus intestinal colonization persists after completion of anti-anaerobic antibiotic treatment in mice. Infect. Control Hosp. Epidemiol. 25:373-379. (Pubitemid 38621082)
33. Stockis A, et al. 1996. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers. Int. J. Clin. Pharmacol. Ther. 34:349-351. (Pubitemid 26271003)
34. Sun X, et al. 2011. Mouse relapse model of Clostridium difficile infection. Infect. Immun. 79:2856-2864.
35. Tannock GW, et al. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156:3354-3359.
36. Tchouaffi-Nana F, et al. 2010. Nitazoxanide inhibits biofilm formation by Staphylococcus epidermidis by blocking accumulation on surfaces. Antimicrob. Agents Chemother. 54:2767-2774.
37. Tupin A, Gualtieri M, Leonetti JP, Brodolin K. 2010. The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site. EMBO J. 29:2527-2537.
38. Vaahtovuo J, Toivanen P, Eerola E. 2003. Bacterial composition of murine fecal microflora is indigenous and genetically guided. FEMS Microbiol. Ecol. 44:131-136. (Pubitemid 37034607)
39. Venuto C, Butler M, Ashley ED, Brown J. 2010. Alternative therapies for Clostridium difficile infections. Pharmacotherapy 30:1266-1278.
40. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307. (Pubitemid 47101025)
41. Zhao Z, et al. 2010. The pharmacokinetics of nitazoxanide active metabolite (tizoxanide) in goats and its protein binding ability in vitro. J. Vet. Pharmacol. Ther. 33:147-153.
42. Zilberg MD, Shorr AF, Kollef MH. 2008. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate. United States, 2000-2005. Emerg. Infect. Dis. 14:929-931. (Pubitemid 351838602)